LI federal judge killed in hit-and-run remembered as trailblazer, devoted mom newsday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from newsday.com Daily Mail and Mail on Sunday newspapers.
Judge Sandra J. Feuerstein
was sworn in by her mother, making them the first mother-daughter pair of judges in the United States.
Judge Annette Elstein of the Immigration Court in New York congratulates her daughter, Sandra J. Feuerstein, after swearing her in as Justice of the New York Supreme Court, Appellate Division. (Image courtesy of the Arthur W. Diamond Law Library, Columbia Law School, and Committee of the Historical Records of the New York County Clerk Inc.)
BROOKLYN (CN) A woman calling herself Harry Potter has been arrested for a hit-and-run that killed a Brooklyn federal judge walking on the sidewalk in Boca Raton, Florida.
Share this article
Share this article
NEW YORK, April 7, 2021 /PRNewswire/ Wolf Popper LLP is investigating potential securities fraud claims on behalf of purchasers of FibroGen, Inc. (NASDAQ: FGEN) common stock.
FibroGen is a biopharmaceutical company. One of its lead drugs is roxadustat, which promotes red blood cell production. Roxadustat is currently approved for sale in China, Japan and Chile for treatment of anemia for patients with chronic kidney disease. FibroGen submitted a New Drug Application (NDA) to the FDA for roxadustat in December 2019. On March 1, 2021, the FDA informed FibroGen that the Cardiovascular and Renal Drugs Advisory Committee would hold an advisory committee meeting to review the NDA for roxadustat. That news was unexpected and caused FibroGen s stock price to fall almost 25% to $38.07 per share.
Wolf Popper LLP Announces Investigation on Behalf of Purchasers of FibroGen, Inc (FGEN) Common Stock prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Shares of Zogenix, Inc. (NASDAQ: ZGNX) traded higher by 200 percent early Friday morning after the company announced top-line results from a phase 3 clinical trial exploring its drug called ZX008 for the treatment of Dravet syndrome.
Zogenix said that its trial met its primary objective of. Read More. Don t Miss Any Updates! News Directly in Your Inbox Subscribe to: